The placebo controlled, random trial investigated the effectiveness of levomilnacipran in treating those who have the disorder, with the trial indicating that all dose groups improved in comparison to the placebo. The treatment is administered once daily and was well tolerated by patients.
Marco Taglietti, research and development president at the Forest Research Institute, believes the results to be “encouraging” and will help support the further treatment of those suffering from major depressive disorder.
Looking for a job in the pharmaceutical industry? Start by clicking here, now